From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs"
BioProcessing Journal · 28.07.2026 · 3
DOI: 10.12665/j161.carson ↗Kurz gefasst
Fachartikel in der Zeitschrift BioProcessing Journal, online erschienen am 28.07.2026. Verfasst von Keith L. Carson.
Abstract (Originalsprache)
When I go to a therapeutic protein meeting, it’s very hard for me to hear these products referred to as “drugs.” But since they are being regulated by CDER, it’s a little easier to swallow. However, calling viral gene vectors and cellular therapies “drugs” is a bridge too far. My advice to my good friends at CBER is to keep calling their products “biologics,” or they may lose all of their regulatory responsibilities to CDER...
Zitieren
APA
Carson, K. L. (2026). From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs". BioProcessing Journal, 3. https://doi.org/10.12665/j161.carson
Vancouver
Carson KL. From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs". BioProcessing Journal. 2026:3. doi:10.12665/j161.carson
BibTeX
@article{Carson2026,
author = {Carson, Keith L.},
title = {From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs"},
journal = {BioProcessing Journal},
year = {2026},
pages = {3},
doi = {10.12665/j161.carson}
}
EUVIMED